GSK and GSK:LN Related Headlines
Go Back- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR17 at Morgan Stanley
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR19 at Barclays
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR20 at Berenberg
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR1,900 at Deutsche Bank
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR22.50 at Citi
- Citi Starts GlaxoSmithKline (GSK:LN) (GSK) at Neutral
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to GBP19.40 at UBS
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR16.75 at Deutsche Bank
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR16 at Morgan Stanley
- Barclays Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Underweight
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR16.60 at Berenberg
- BofA Securities Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR16 at Deutsche Bank
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR21 at Jefferies
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR19 at UBS
- Barclays Reiterates Equalweight Rating on GlaxoSmithKline (GSK:LN) (GSK)
- Deutsche Bank Reiterates Hold Rating on GlaxoSmithKline (GSK:LN) (GSK)
- UBS Reiterates Neutral Rating on GlaxoSmithKline (GSK:LN) (GSK)
- GlaxoSmithKline (GSK:LN) (GSK) PT Lowered to INR14 at JPMorgan
- GlaxoSmithKline (GSK:LN) (GSK) PT Lowered to INR12.90 at Morgan Stanley
- Deutsche Bank Reiterates Hold Rating on GlaxoSmithKline (GSK:LN) (GSK)
- GlaxoSmithKline (GSK:LN) (GSK) PT Raised to INR15.80 at Goldman Sachs
- Deutsche Bank Reiterates Hold Rating on GlaxoSmithKline (GSK:LN) (GSK)

